We are a company developing allogeneic CAR-T cells to treat refractory diseases represented by advanced solid tumors. We believe that compared with small molecule chemical drugs and large molecule biological drugs, cell drugs have the potential to achieve breakthroughs in many diseases that are currently clinically untreatable. By focusing on innovative, cell-based treatments, we aim to transcend the limitations of traditional therapies, offering hope and a new lease on life to those facing the